{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:45:50Z","timestamp":1793051150782,"version":"4.5.0"},"reference-count":57,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of North Carolina at Charlotte\u2014Charlotte Faculty Research Grant and Technology Transfer Office"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Ovarian cancer is a deadly gynecological malignancy that will affect about 21,000 women and result in almost 153,000 deaths in the United States in 2025. New clinical tools that facilitate early diagnosis and treatment of ovarian malignancies will significantly help reduce mortality and improve current long-term survival rates. We utilized a previously identified single-strand DNA aptamer RLA01 that binds and internalizes into target epithelial ovarian cancer cells to label PLGA-based nanoparticles and determine their ability to selectively target EOC cells and deliver payloads for cellular internalization. Nanoparticles labeled with RLA01 significantly enhanced cellular uptake 20\u201385% by receptor-mediated endocytosis into target EOC Caov-3 cells and inhibited cellular uptake in non-target HOSE 6-3 cells. Further, labeling of paclitaxel-loaded nanoparticles with RLA01 significantly decreased cell proliferation and induced apoptosis. A preliminary pilot study looking at the in vivo stability of aptamers demonstrated their ability to promote retention and honing of nanoparticles at tumors. These data demonstrate the effective combinatorial use of aptamer RLA01 and nanoparticle technologies for the direct targeting of tumor cell populations both in vitro and in vivo.<\/jats:p>","DOI":"10.3390\/biom15081123","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T10:48:08Z","timestamp":1754304488000},"page":"1123","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Aptamer-Coated PLGA Nanoparticles Selectively Internalize into Epithelial Ovarian Cancer Cells In Vitro and In Vivo"],"prefix":"10.3390","volume":"15","author":[{"given":"Gregory","family":"Benedetto","sequence":"first","affiliation":[{"name":"Center for Biomedical Engineering and Sciences, University of North Carolina at Charlotte, 9201 University Blvd., Charlotte, NC 28223, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Fowler","sequence":"additional","affiliation":[{"name":"Center for Biomedical Engineering and Sciences, University of North Carolina at Charlotte, 9201 University Blvd., Charlotte, NC 28223, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Langdon","sequence":"additional","affiliation":[{"name":"Center for Biomedical Engineering and Sciences, University of North Carolina at Charlotte, 9201 University Blvd., Charlotte, NC 28223, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Raine","sequence":"additional","affiliation":[{"name":"Center for Biomedical Engineering and Sciences, University of North Carolina at Charlotte, 9201 University Blvd., Charlotte, NC 28223, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly Lynne","family":"White","sequence":"additional","affiliation":[{"name":"Center for Biomedical Engineering and Sciences, University of North Carolina at Charlotte, 9201 University Blvd., Charlotte, NC 28223, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Ogle","sequence":"additional","affiliation":[{"name":"Center for Biomedical Engineering and Sciences, University of North Carolina at Charlotte, 9201 University Blvd., Charlotte, NC 28223, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Garmon","sequence":"additional","affiliation":[{"name":"Center for Biomedical Engineering and Sciences, University of North Carolina at Charlotte, 9201 University Blvd., Charlotte, NC 28223, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Ogle","sequence":"additional","affiliation":[{"name":"Center for Biomedical Engineering and Sciences, University of North Carolina at Charlotte, 9201 University Blvd., Charlotte, NC 28223, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Richardson","sequence":"additional","affiliation":[{"name":"Center for Biomedical Engineering and Sciences, University of North Carolina at Charlotte, 9201 University Blvd., Charlotte, NC 28223, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"ref_1","unstructured":"(2025). SEER Cancer Statistics Factsheets: Ovary Cancer, American Cancer Society."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1100\/tsw.2011.112","article-title":"Ovarian epithelial cancer stem cells","volume":"11","author":"Conic","year":"2011","journal-title":"Sci. World J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s12672-010-0054-2","article-title":"Microenvironment and pathogenesis of epithelial ovarian cancer","volume":"1","author":"Saad","year":"2010","journal-title":"Horm. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian cancer","volume":"374","author":"Hennessy","year":"2009","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/sj.bjc.6601494","article-title":"Primary ovarian cancer chemotherapy: Current standards of care","volume":"89","author":"McGuire","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.2174\/138161212802002788","article-title":"Advances in epithelial ovarian cancer therapy","volume":"18","author":"Kroep","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1038\/bjc.2012.207","article-title":"In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival","volume":"106","author":"Bicaku","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_8","first-page":"25","article-title":"Targeted treatment of recurrent platinum-resistant ovarian cancer: Current and emerging therapies","volume":"3","author":"Edwards","year":"2011","journal-title":"Cancer Manag. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2013.05.029","article-title":"Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer","volume":"131","author":"Markman","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.2174\/138161212802002689","article-title":"The role of bevacizumab in advanced epithelial ovarian cancer","volume":"18","author":"Kroep","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_11","first-page":"153","article-title":"Current status of intraperitoneal antineoplastic drug delivery","volume":"134","author":"Markman","year":"2007","journal-title":"Cancer Treat. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","article-title":"Intraperitoneal antineoplastic drug delivery: Rationale and results","volume":"4","author":"Markman","year":"2003","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.2174\/138161212802002814","article-title":"Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer","volume":"18","author":"Monk","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17356","DOI":"10.1073\/pnas.0809154105","article-title":"Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles","volume":"105","author":"Dhar","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"21832","DOI":"10.1021\/am5026243","article-title":"Aptamer-Functionalized Gold Nanoparticles As Photoresponsive Nanoplatform for Co-Drug Delivery","volume":"6","author":"Shiao","year":"2014","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2041731413503357","DOI":"10.1177\/2041731413503357","article-title":"Silica-based mesoporous nanoparticles for controlled drug delivery","volume":"4","author":"Kwon","year":"2013","journal-title":"J. Tissue Eng."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1039\/C1NR11265A","article-title":"One-step engineering of silver nanoclusters-aptamer assemblies as luminescent labels to target tumor cells","volume":"4","author":"Yin","year":"2012","journal-title":"Nanoscale"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1073\/pnas.1011379108","article-title":"Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo","volume":"108","author":"Dhar","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1016\/j.biomaterials.2011.07.004","article-title":"Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery","volume":"32","author":"Guo","year":"2011","journal-title":"Biomaterials"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.addr.2010.10.008","article-title":"PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect","volume":"63","author":"Acharya","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.addr.2013.09.019","article-title":"Nanomedicine therapeutic approaches to overcome cancer drug resistance","volume":"65","author":"Markman","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: An overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.addr.2007.06.003","article-title":"Biodegradable nanoparticles for cytosolic delivery of therapeutics","volume":"59","author":"Vasir","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1021\/ar900101s","article-title":"Aptamers generated from cell-SELEX for molecular medicine: A chemical biology approach","volume":"43","author":"Fang","year":"2010","journal-title":"Acc. Chem. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"748913","DOI":"10.1155\/2012\/748913","article-title":"Challenges and opportunities for small molecule aptamer development","volume":"2012","author":"McKeague","year":"2012","journal-title":"J. Nucleic Acids"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00432-014-1767-3","article-title":"Cancer active targeting by nanoparticles: A comprehensive review of literature","volume":"141","author":"Bazak","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.addr.2010.03.003","article-title":"Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates","volume":"62","author":"Lee","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.tibtech.2011.06.009","article-title":"Molecular aptamers for drug delivery","volume":"29","author":"Tan","year":"2011","journal-title":"Trends Biotechnol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.2174\/092986711797189547","article-title":"Tumor-targeted drug delivery with aptamers","volume":"18","author":"Zhang","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"10472","DOI":"10.1039\/c2cc35042d","article-title":"Nucleic acid aptamers: An emerging frontier in cancer therapy","volume":"48","author":"Zhu","year":"2012","journal-title":"Chem. Commun. (Camb.)"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/CAD.0b013e32834a4554","article-title":"Targeting of nanoparticles in cancer: Drug delivery and diagnostics","volume":"22","author":"Talekar","year":"2011","journal-title":"Anticancer. Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Fu, Z., and Xiang, J. (2020). Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239123"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial","volume":"360","author":"Group","year":"2002","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11523-015-0371-z","article-title":"Aptamer-Functionalized Nanoparticles as Smart Bombs: The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment","volume":"10","author":"Benedetto","year":"2015","journal-title":"Target. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Li, Y., Zhao, J., Xue, Z., Tsang, C., Qiao, X., Dong, L., and Gao, Y. (2022). Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.1053984"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1038\/am.2014.12","article-title":"Aptamer-conjugated nanomaterials for specific cancer cell recognition and targeted cancer therapy","volume":"6","author":"Liu","year":"2014","journal-title":"NPG Asia Mater."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Narwade, M., Shaikh, A., Gajbhiye, K.R., Kesharwani, P., and Gajbhiye, V. (2023). Advanced cancer targeting using aptamer functionalized nanocarriers for site-specific cargo delivery. Biomater. Res., 27.","DOI":"10.1186\/s40824-023-00365-y"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Sheikh, A., Md, S., and Kesharwani, P. (2022). Aptamer grafted nanoparticle as targeted therapeutic tool for the treatment of breast cancer. Biomed. Pharmacother., 146.","DOI":"10.1016\/j.biopha.2021.112530"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"32231","DOI":"10.1021\/acsomega.3c04345","article-title":"Recent Advancements of Aptamers in Cancer Therapy","volume":"8","author":"Venkatesan","year":"2023","journal-title":"ACS Omega"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wong, K.Y., Wong, M.S., and Liu, J. (2024). Aptamer-functionalized liposomes for drug delivery. Biomed. J., 47.","DOI":"10.1016\/j.bj.2023.100685"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1517\/14656566.2012.651127","article-title":"Enhancing intracellular taxane delivery: Current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer","volume":"13","author":"Guarneri","year":"2012","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1517\/14712598.2010.481666","article-title":"Rexin-G, a targeted genetic medicine for cancer","volume":"10","author":"Gordon","year":"2010","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1158\/0008-5472.CAN-06-3463","article-title":"Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells","volume":"67","author":"Deng","year":"2007","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/ijc.2910530628","article-title":"Conditional expression and oncogenicity of c-myc linked to a CD2 gene dominant control region","volume":"53","author":"Stewart","year":"1993","journal-title":"Int. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nsmb.2842","article-title":"Dicer-microRNA-Myc circuit promotes transcription of hundreds of long noncoding RNAs","volume":"21","author":"Zheng","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ramanathan, R., Hamburg, S.I., Borad, M., Seetharam, M., Kundranda, M., Lee, P., Frelund, P., Gibert, M., Mast, C., and Semple, S. (2013, January 6\u201310). A Phasi I Dose Escalation Study of TKM-080301, a RNA Therapeutic Directed Aptamer Against PLK1, in Patients with Advanced Solid Tumors. Proceedings of the 104th Annual Meeting of the American Association of Cancer Research AACR, Washington, DC, USA.","DOI":"10.1158\/1538-7445.AM2013-LB-289"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-2571(00)00013-3","article-title":"The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting","volume":"41","author":"Maeda","year":"2001","journal-title":"Adv. Enzyme Regul."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: Progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.coph.2009.07.006","article-title":"Aptamers: A new class of oligonucleotides in the drug discovery pipeline?","volume":"9","author":"Dausse","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1021\/cn100114k","article-title":"In vitro Selection of DNA Aptamers to Glioblastoma Multiforme","volume":"2","author":"Bayrac","year":"2011","journal-title":"ACS Chem. Neurosci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1089\/nat.2014.0522","article-title":"Identification of epithelial ovarian tumor-specific aptamers","volume":"25","author":"Benedetto","year":"2015","journal-title":"Nucleic Acid. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"9137","DOI":"10.1021\/ja801951p","article-title":"Aptamer-facilitated biomarker discovery (AptaBiD)","volume":"130","author":"Berezovski","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Van Simaeys, D., Lopez-Colon, D., Sefah, K., Sutphen, R., Jimenez, E., and Tan, W. (2010). Study of the molecular recognition of aptamers selected through ovarian cancer cell-SELEX. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013770"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/jmg.2009.066944","article-title":"Apoptosis and cancer: Mutations within caspase genes","volume":"46","author":"Ghavami","year":"2009","journal-title":"J. Med. Genet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9101","DOI":"10.1074\/jbc.M511049200","article-title":"Nitric oxide-dependent negative feedback of PARP-1 trans-activation of the inducible nitric-oxide synthase gene","volume":"281","author":"Yu","year":"2006","journal-title":"J. Biol. Chem."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/8\/1123\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:22:43Z","timestamp":1760034163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/8\/1123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":57,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["biom15081123"],"URL":"https:\/\/doi.org\/10.3390\/biom15081123","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]}}}